To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation.

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

May 30, 2023

Study Completion Date

May 30, 2023

Conditions
Cirrhosis, Liver
Interventions
DRUG

Midodrine Oral Tablet

Midodrine starting at 0.25mg/kg/day in 2-3 divided doses, increased to 0.5mg/kg/day after 7 days if MAP does not increase by \>10% ; Midodrine dosage will be decreased by 25% in case of arterial hypertension (\>95th centile BP for the age). Also Standard medical therapy as per departmental protocol will be continued

OTHER

Standard Medical Treatment

"Albumin infusion 1g/kg/day - maximum 20gm/day and repeat till serum albumin reaches 2.8g/dl If serum albumin is \< 2.8g/dl SBP - Day 1 and Day 3~For Ascites :~Restriction of sodium to \< 2meq/kg/day A combination of a distal-acting diuretic (spironolactone, 3-6 mg/ kg/day) and loop-acting diuretic (furosemide,0.5- 2 mg/kg per day) was given with dose escalation by one step at a time if there is no decrease in weight (by ≥ 0.5 %/day) after 5-7 days Therapeutic paracentesis (\>50ml/kg) with infusion of albumin (8 g/L) performed for tense, symptomatic ascites~For Spontaneous Bacterial Peritonitis :~IV antibiotics for 7 days Albumin Infusion on Day 1 and Day 3"

Trial Locations (1)

110070

Institute of liver and biliary sciences, New Delhi

All Listed Sponsors
lead

Institute of Liver and Biliary Sciences, India

OTHER

NCT05287100 - To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation. | Biotech Hunter | Biotech Hunter